Drug Database
ME

methylphenidate (Methydur)

✓ Approved

Durect · SLC6A2 · 小分子

什么是 methylphenidate?

methylphenidate 是一种小分子,由Durect研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Methydur
公司Durect
药物类别小分子
分子靶点SLC6A2, SLC6A3
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

methylphenidate 作用于 2 个分子靶点:

SLC6A2solute carrier family 6 member 2 (NAT1, NET)
SLC6A3solute carrier family 6 member 3 (PKDYS, DAT1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

methylphenidate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersAttention deficit hyperactivity disorder✓ Approved

相关研究文献

PubMedChild and adolescent psychiatry and mental health2026-11-18

Impact of nutritional factors on the pharmacokinetics of ADHD medication - a systematic review.

Schepp Michael M, Engel Melanie M, Hirschbeck Anna A, Müller-Stierlin Annabel A et al.

Attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy relies primarily on stimulant medications such as methylphenidate and amphetamines. Pharmacokinetic variability may influence therapeutic efficacy and tolerability. Nutritional factors, including food intake and alcohol consumption, may alter drug absorption, metabolism, and systemic exposure, yet these interactions have not been systematically synthesized across ADHD medications. A systematic literature search was conducted across PubMed, Web of Science, Scopus, Embase, and Cochrane CENTRAL. Clinical studies in humans investigating the pharmacokinetics of ADHD medications under defined nutritional conditions (e.g., fasting vs. fed states or alcohol co-administration) were included. 33 clinical studies met the inclusion criteria. Most included studies were small, single-dose pharmacokinetic studies conducted in healthy adults, and evidence under steady-state conditions or in patients with ADHD was limited. Modified-release formulations showed greater formulation-specific variability, including changes in tmax, Cmax, early exposure, and the shape of the concentration-time profile despite comparatively preserved total AUC in several studies. Eligible published evidence for non-stimulant ADHD medications was sparse, with only one eligible study each for extended-release clonidine and viloxazine. Human studies investigating alcohol interactions were predominantly available for methylphenidate and demonstrated increased methylphenidate exposure and formation of ethylphenidate. Food intake affects the pharmacokinetics of most ADHD medications primarily by affecting the rate rather than the extent of absorption. Alcohol-methylphenidate interactions are clinically significant. Consistent administration conditions and patient counselling are important to optimize therapeutic outcomes.

PMID 43046269
阅读全文 →
PubMedEuropean child & adolescent psychiatry2026-11-15

When extended-release methylphenidate underperforms: three children with ADHD and gastrointestinal disease.

Caci Hervé H

Methylphenidate (MPH) is the first-line pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children, available in immediate-release (IR) and extended-release (ER) formulations with distinct release profiles. Whether gastrointestinal pathology might selectively affect one or the other has received little clinical attention. We here report three patients with ADHD followed in a single paediatric centre, each with a gastrointestinal disease affecting either absorption (cystic fibrosis) or motility (idiopathic gastroparesis, and gastroparesis in a child with Charcot-Marie-Tooth disease type 1 A). In all three, IR-MPH doses produced clearer per-dose responses than ER-MPH at some stage of follow-up; multiple daily IR-MPH doses achieved successful overall management in Cases 1 and 2, whereas Case 3 required a combined ER-IR regimen due to unmanageable peak-and-trough fluctuations under IR monotherapy. In the cystic fibrosis case, the introduction of CFTR-modulator triple therapy was followed, after a delay, by a within-patient reversal of the IR/ER preference. These observations raise the hypothesis that gastrointestinal disorders affecting upper gastrointestinal transit or absorption may alter the relative clinical performance of different MPH formulations, which deserves explicit consideration when selecting a formulation.

PMID 43033244
阅读全文 →
PubMedFrontiers in neuroscience2026-11-15

Stress-induced dorsal striatal dopamine release is associated with changes in functional connectivity to the prefrontal cortex in nicotine-dependent individuals-a preliminary report.

Fan Siyan S, Kim Su Jin SJ, Zakiniaeiz Yasmin Y, Hoye Jocelyn J et al.

The neural mechanism linking stress to addiction pathophysiology remains unclear. A proposed pathway involves stress-induced dopamine (DA) transmission impairing inhibitory control, leading to relapse. Lipopolysaccharide (LPS), a biological stressor inducing systemic inflammation, amplifies DA release. Our prior study demonstrated this effect in smokers. Using the same cohort, we investigated whether DA transmission mediates acute stress effects and impacts striatal-prefrontal functional connectivity (FC) in brain regions governing reward, inhibition, and decision-making. Using a within-subject, multimodal design, we collected PET and resting-state functional MRI (rs-fMRI) scans in 8 smokers (6 females; mean age: 32 ± 3.6 years). Stress was induced using LPS; plasma cortisol indexed level of stress. DA release was measured in striatal subregions using [11C]raclopride PET before and after methylphenidate administration, while striatal-prefrontal functional connectivity was assessed using seed-based rs-fMRI. Each participant completed three PET scans (one baseline and two post-methylphenidate scans following LPS or placebo [PCBO] pretreatment) and two rs-fMRI scans (LPS and PCBO), resulting in a total of 24 PET scans and 16 rs-fMRI scans. LPS elevated cortisol and DA release in striatum compared to Placebo (p < 0.05). Cortisol increases correlated with dorsal striatal DA release (r = 0.708, p = 0.04). FC analyses revealed enhanced FC between dorsal striatum and ventral medial prefrontal cortex (vmPFC) (p < 0.001, FDR-corrected), and between whole striatum and dorsal lateral PFC (dlPFC) (p < 0.001, FDR-corrected). Nonlinear associations showed FC initially increased with stress but plateaued at higher stress levels. Stress-induced changes in DA release within dorsal striatum influence stress-related alterations in frontal-striatal FC. Our present findings in a limited cohort lead us to hypothesize more broadly that stress alterations in frontal-striatal FC reflect adaptation, whereas excessive stress may disrupt circuits, potentially contributing to addictive behaviors such as smoking. While the present pilot study demonstrates the potential value of PET and rs-fMRI to connect neurotransmitter action to downstream cortical activity future work will be essential to confirm the reproducibility and relevance of the observed associations.

PMID 43032601
阅读全文 →
PubMedPsychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata2026-11-15

[Pharmacological treatment options for adult attention-deficit/hyperactivity disorder].

Réthelyi János J, Pulay Attila József AJ

Adult attention-deficit/hyperactivity disorder (ADHD) is a relatively common and largely underdiagnosed neurodevelopmental disorder characterized by symptoms of inattention, impulsivity, impaired activity regulation, and emotional dysregulation, which may cause functional impairment throughout the lifespan. In Hungary, the condition is estimated to affect approximately 250 000 adults, and in many cases it does not lead to help-seeking until young adulthood. Its clinical significance extends well beyond attentional difficulties: ADHD is frequently associated with substance use disorders, mood and anxiety disorders, and, in the longer term, an increased risk of cardiovascular and metabolic conditions. Recognition and appropriate treatment of ADHD therefore offer not only an opportunity for symptom reduction and improved functioning, but also for the prevention of psychiatric and substance use-related complications. The cornerstone of treatment is a multimodal approach: pharmacotherapy is complemented by psychoeducation, structured interventions targeting everyday functioning, and psychotherapy when indicated. In this review, we provide an overview of the currently available pharmacological treatment options for adult ADHD, including the assessments required before treatment initiation, stimulant and non-stimulant medications, and other pharmacological options. We also discuss the benefits, challenges, and clinical significance of long-term pharmacological management. Keywords: attention-deficit/hyperactivity disorder; ADHD; pharmacological treatment; stimulant; methylphenidate; lisdexamfetamine; atomoxetine; antidepressant.

PMID 43033119
阅读全文 →
PubMedBrain communications2026-11-15

Pharmacological treatments in disorders of consciousness.

Saleh Christian C, Seyfzadeh Fatemeh F, Szymkowicz Emilie E, Alnagger Naji N et al.

Disorders of consciousness (DoC) are among the most severe and devastating neurological conditions. The poorly understood underlying pathophysiology of DoC renders the search for adequate treatment options particularly difficult. The aim of this narrative review is to provide an overview of currently available pharmacological treatments, report the limitations of current research and discuss future directions, notably potential new treatments, advances in modelling approaches, potential mechanisms of action and the development of a standardized registry. We review pharmacological treatments that promote the recovery of consciousness in patients with DoC acting on dopaminergic (amantadine, levodopa, apomorphine, methylphenidate, bromocriptine, modafinil and selegiline) and GABAergic (zolpidem, baclofen and midazolam) pathways, as well as other pharmacological treatments (tricyclic antidepressants, anticonvulsants and simvastatin) and the combination of different treatments. The literature includes a limited number of randomized controlled trials (RCTs) alongside a large body of retrospective studies and case reports, which are classified as class IV evidence. Reported improvements in arousal or responsiveness are inconsistent, reflecting marked heterogeneity in patient populations, dosing regimens and outcome measures. Risk-of-bias assessment indicated that 12 of 22 RCTs (∼55%) exhibit some concerns or a high risk of bias. Multiple correspondence analysis yielded a descriptive mapping of RCT characteristics, demonstrating how pharmacological trials in DoC are grouped. Although mechanistic hypotheses converge on dopaminergic, GABAergic and thalamocortical modulation, the current literature on pharmacological treatments in DoC remains poorly reproducible. Given the significant methodological variability (e.g. study design, patient characteristics and outcome measures) across studies, current evidence does not allow firm conclusions regarding the most effective consciousness-enhancing pharmacological treatments in DoC. To make informed decisions in terms of pharmacological treatments and move towards personalized care for patients with DoC, rigorously designed multicentre controlled trials with harmonized outcome measures conducted with mechanistic and computational approaches are required. This can be achieved through an international registry to standardize data collection and improve reproducibility and replicability.

PMID 43032840
阅读全文 →
PubMedBMC psychiatry2026-11-14

Acute effects of immediate-release methylphenidate on QbTest performance in adults with untreated ADHD and longstanding polysubstance use: a randomized double-blind placebo-controlled crossover study.

Löhman Monica M, Domingo Blanca B, Jansson Lennart L

Although methylphenidate (MPH) is a first-line treatment for adult attention-deficit/hyperactivity disorder (ADHD) in Europe, evidence in individuals with co-occurring ADHD and substance use disorder (SUD) remains limited, particularly in those with longstanding polysubstance use. This study examined the acute effects of immediate-release methylphenidate (IR-MPH) versus placebo on cognitive performance in this population. In this randomized, double-blind, placebo-controlled crossover study, 39 adults with untreated ADHD and longstanding polysubstance use completed the QbTest before and 80 min after a single 20-mg dose of IR-MPH and placebo on separate study days. Objective outcomes were the cardinal QbTest parameters QbActivity, QbInattention, and QbImpulsivity. Subjective outcomes included self-rated expected performance, perceived performance, perceived mental effort, perceived benefit from the study medication, and task comprehension. Repeated-measures analyses of variance (ANOVA) and paired-samples t-tests were used to compare outcomes across conditions. Compared with baseline, IR-MPH significantly improved QbInattention [mean difference 1.00, 95% CI (0.55-1.45), p < 0.001], QbActivity [mean difference 0.83, 95% CI (0.37-1.28), p < 0.001], and QbImpulsivity [mean difference 0.83, 95% CI (0.12-1.55), p < 0.001]. These effects remained significant after adjustment for placebo effects. Placebo was associated with significant improvement only in reaction time [mean difference 35.15, 95% CI (2.37-67.84), p < 0.029]. Expected performance and perceived performance improved after IR-MPH but not after placebo, whereas mental effort decreased after both conditions. Participants reported greater perceived benefit from IR-MPH than from placebo. No QbTest order effects were observed. IR-MPH was associated with short-term improvements in objective QbTest performance in adults with untreated ADHD and longstanding polysubstance use, whereas placebo effects were limited on objective outcomes and were more evident in subjective experience. These findings support the inclusion of objective assessments alongside self-report when evaluating early treatment response in clinically complex adults with ADHD and co-occurring SUD. NCT02477280 in ClinicalTrial.gov, registered on June 22, 2015.

PMID 43026516
阅读全文 →

注册免费账户还可查看另外 8779 篇文献

免费注册查看全部文献 →

了解更多methylphenidate